**Drug Use Research & Management Program**
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
**Phone** 503-947-5220 | **Fax** 503-947-1119

**Oregon Drug Use Review / Pharmacy & Therapeutics Committee**
Thursday, May 31, 2012 1:00-4:00 PM
Clackamas Community Training Center
29353 SW Town Center Loop East
Wilsonville, OR 97070

**MEETING MINUTES**

**Members Present:** Andris Antoniskis, MD; Tracy Klein, PhD, FNP; Phillip Levine, PhD; Meena Mital, MD; William Origer, MD; David Pass, MD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh;
**Staff Present:** Bing-Bing Liang, PharmD; Roger Citron, RPh; Megan Herink, PharmD, BCPS; Kathy Ketchum, RPh, MPA: HA; Ted Williams, PharmD; Valerie Smith, Richard Holsapple, RPh; Ralph Magrish, MPA
**Staff Present by Phone**: Kathy Sentena, PharmD
**Audience:** Barry Benson (Merck); Nathan Wood, MD (Merck); Shane Hall (Purdue); Venus Holder (Eli Lilly); John Brokers (Eli Lilly); Deron Grothe (Teva); Greg Marchak (GSK); Joanna Turbeville (GSK); Bruce Smith (GSK); Rob Pearson; Chris Adams (Lundbeck); Reenie Traether (Lundbeck); Cheryl Fletcher (Abbott); Deborah Griffs (Abbott); Jeana Colabianchi (Sunovion); David Barba (Forest); Kathy Kirk (OPMC); Richard Kosesan; Tzeli Triantafillou; Anne Marie Licos (MedImmune); Barbara Felt; Mike Willett (Pfizer); Dr. Robert Mendelson (FAAP); Dr. William Lavia (FAAP)

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff.**

I. CALL TO ORDER
- a. The meeting was called to order at approximately 1pm.
- b. Conflict of interest declarations were reviewed and no new conflicts were reported.
- c. The April 26, 2012 meeting minutes were reviewed.

**ACTION:** Approved as is.

II. DUR ACTIVITIES
- a. Mr. Magrish reported that DMAP will post an Invitation to Bid (ITB) for a generic preferred drug list will be posted soon as a result of a budget note from the special 2012 Legislative Session.
- b. Mr. Holsapple presented the ProDUR report.
- c. Dr. Williams presented the RetroDUR report and recommended doing some housekeeping to the report and cleaning up some outdated pieces.

***ACTION:** Recommendations approved.
- d. Mr. Citron presented the Quarterly Utilization Reports.
- e. Ms. Ketchum presented the ICS/LABA Policy Evaluation recommending continuing PA requirements for ICS/LABA combinations, consider loosening electronic criteria to require only a diagnosis of COPD or prior anti-cholinergic inhaler use, implement RetroDUR education lettering on LABA monotherapy in the absence of COPD indicators, further study to evaluate patient outcomes after encountering a PA for ICS/LABA, and further study of patients without a diagnosis.

**Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)*

***ACTION:** Recommendations approved

f. Dr. Sentena presented the Oregon State Drug Review on the current findings in the off-label use of Atypical Antipsychotics.

III. HOUSEKEEPING

a. Mr. Citron recommended removing the Ondansetron quantity limit.

***ACTION:** The Committee approved recommendation after executive session.

IV. OLD BUSINESS

a. Dr. Sentena presented Synagis Drug Use Evaluation recommending requiring prior authorization for use of palivizumab in compliance with AAP recommendations and limiting payment to pharmacy providers to eliminate the possibility of duplicate payment between pharmacy and medical providers. Dr. Mendleson presented public comment. Bill Lavia from MedImmune presented public comment.

***ACTION:** All in favor with additional recommendation of requiring at least 10 tests in a week to determine season onset/offset.

V. NEW BUSINESS

a. Dr. Sentena presented Asthma Controller Class Update recommending removing Aerobid due to no rebateable product availability, verify SRA on Pulmicort,remove if not contracted and grandfather current clients, and update PA criteria. Barbara Felt with GlaxoSmithKline presented public comment.

***ACTION:** The Committee approved recommendation after executive session.

b. Dr. Herink presented Seizure Medication Class Update and New Drug Reviews recommending adding clobazam to the oral anticonvulsant class on the PDL with PA for diagnosis verification, make ezogabine second line non-preferred oral anticonvulsant to ensure appropriate use and continue to prefer generic alternatives when appropriate. Barbara Felt with GlaxoSmithKline presented public comment.

***ACTION:** The Committee approved recommendation after executive session.

c. Ms. Ketchum presented Topical Antiparasite Class Update and New Drug Reviews recommending spinosad 0.9% topical suspension and ivermectin 0.5% lotion non-preferred due to insufficient evidence of effectiveness or safety relative to permethrin.

***ACTION:** The Committee approved recommendation after executive session.

d. Dr. Liang presented Other Lipid Lowering Agents Abbreviated Class Review recommending adding Other Lipid Lowering Agents to the PDL and include cholestyramine as the preferred bile acid sequestrant, include gemfibrozil, fenofibrate tablets, fenofibric acid tablets and Triplix pending supplemental rebate contract negotiations, make Niaspan and Niacor preferred, make ezetimibe and Lovaza non-preferred. Rob Pearson with GlaxoSmithKline presented public comment. Deborah Griffis with Abbott presented public comment. Robert Shipiro with OHSU submitted written public comment. Nancy Curosh, MD submitted written public comment.

***ACTION:** All in favor with deferment of fish oil action pending review of evidence for other indications.

VI. HERC COVERAGE GUIDANCE

a. Dr. Livingston and Dr. Alison Little presented guidelines on Low Back Pain. John Brokars with Eli Lilly presented public comment. The Committee recommended specifying acute versus chronic back pain, a requirement of documentation of improved functionality for coverage, requirement of initial risk assessment and that a caveat be included for the herbal recommendations that they are not regulated by the FDA.

VII. The meeting adjourned at approximately 4:50 pm.

**Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)*